Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > BUSINESS
BUSINESS
- Eli Lilly Receives Positive Opinion from CHMP for Alimta as Maintenance Therapy for NSCLC
October 7, 2011
- Aiming for 6% Yearly Growth by Rivaroxaban Launching: Bayer AG
October 6, 2011
- Ranbaxy Starts Selling Daiichi Sankyo Drugs in Italy
October 6, 2011
- Eli Lilly Japan Applies for Approval of Fast-Acting Zyprexa Intramuscular Inj.
October 6, 2011
- Nihon Chouzai Introduces Catalog Retailing at All Its Stores
October 6, 2011
- Takeda President Hasegawa Says Innovation Will Take Place in Developing Countries
October 5, 2011
- Ono and Germany’s Merck Enter into License Agreements to Boost Priority Fields
October 5, 2011
- Rating Companies Downgrade Takeda following Acquisition of Nycomed
October 4, 2011
- Mochida’s New 3-Year Business Plan Aims for Sales of ¥100 Bil. in FY2013
October 4, 2011
- Shionogi Announces International Industry-Academic Collaboration Program
October 4, 2011
- Taisho HD Listed on 1st Section of Tokyo Stock Exchange with Closing Price of ¥6,750 on 1st Day of Trading
October 4, 2011
- Eisai Sets Up Aricept Dept. to Boost Japan Marketing Efforts
October 3, 2011
- Takeda Completes Acquisition of Nycomed, Global Rx Sales Ranking Up to 12th
October 3, 2011
- Avastin Recommended as 1st Line Treatment for Advanced Ovarian Cancer in Europe: Roche
October 3, 2011
- GSK Is Able to Supply Cervarix for Vaccination at Subjects’ Own Expense
October 3, 2011
- Number of MRs in Japan Breaks 60,000 for 1st Time: MREAC
October 3, 2011
- Afinitor Meets Primary Endpoint for AML in Int’l PIII Trial for TSC patients : Novartis
October 3, 2011
- Maruho Establishes US Subsidiary
October 3, 2011
- Ono: Corebeta for Inj. 12.5 mg for Improving Image Quality in Coronary CT Angiography
October 3, 2011
- Novartis Pharma: COPD Treatment Onbrez Inhalation Capsules
October 3, 2011
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…